Skip to Content

Analysis of the cost- effectivenes of novel antiandrogens treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC)

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top